We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Evgen Pharma has received full regulatory approval for its STAR trial, which will investigate the company’s lead asset to treat acute respiratory distress syndrome (ARDS) in patients with suspected COVID-19.